ArticleProceedings of the National Academy of Sciences of the United States of America2008
A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
179 citing papers in PubMed, 313 citations in OpenAlex.
- Changes in the gut microbiome associated with infliximab in patients with bipolar disorder.Brain and behavior · 2021Trial
- Longitudinal development of the airway microbiota in infants with cystic fibrosis.Scientific reports · 2019Trial
- A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.Orphanet journal of rare diseases · 2013Trial
- Co-infection withISME communications · 2026Article
- Auto-aggregation inmBio · 2025Article
- Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.Clinical microbiology reviews · 2024Review
- Dpr-mediated HJournal of bacteriology · 2024Article
- Exploring the microbiota difference of bronchoalveolar lavage fluid between community-acquired pneumonia with or without COPD based on metagenomic sequencing: a retrospective study.BMC pulmonary medicine · 2024Article
- Association between oral microbiome and five types of respiratory infections: a two-sample Mendelian randomization study in east Asian population.Frontiers in microbiology · 2024Article
- Effect ofFrontiers in microbiology · 2024Article
- Myxinidin-Derived Peptide against Biofilms Caused by Cystic Fibrosis Emerging Pathogens.International journal of molecular sciences · 2023Article
- Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system.eLife · 2023Article
- Crosslink between SARS-CoV-2 replication and cystic fibrosis hallmarks.Frontiers in microbiology · 2023Review
- The P. aeruginosa effector Tse5 forms membrane pores disrupting the membrane potential of intoxicated bacteria.Communications biology · 2022Article
- Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation.Journal of the Pediatric Infectious Diseases Society · 2022Review
- Enterococcus faecalis Antagonizes Pseudomonas aeruginosa Growth in Mixed-Species Interactions.Journal of bacteriology · 2022Article
- Pseudomonas aeruginosa polysaccharide Psl supports airway microbial community development.The ISME journal · 2022Article
- Putative RNA Ligase RtcB Affects the Switch between T6SS and T3SS inInternational journal of molecular sciences · 2021Article
- Multi-Omics Study of Keystone Species in a Cystic Fibrosis Microbiome.International journal of molecular sciences · 2021Article
- Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
119 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung disease is the leading cause of morbidity and mortality in cystic fibrosis (CF) patients. A modest number of bacterial pathogens have been correlated with pulmonary function decline; however, microbiological and molecular evidence suggests that CF airway infection is polymicrobial. To obtain a more complete assessment of the microbial community composition and dynamics, we undertook a longitudinal study by using culture-independent and microbiological approaches. In the process, we demonstrated that within complex and dynamic communities, the Streptococcus milleri group (SMG) can establish chronic pulmonary infections and at the onset of 39% of acute pulmonary exacerbations, SMG is the numerically dominant pathogen. We report the comprehensive polymicrobial community dynamics of a CF lung infection in a clinically relevant context. If a given organism, such as Pseudomonas aeruginosa, becomes resistant to antibiotic therapy, an alternative treatment avenue may mediate the desired clinical response by effectively managing the composition of the microbial community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.